

Supplemental Table 1: Comparison of UK LDFRT regimens to TPF containing induction regimens.

Trial	Induction Regimen	Definitive Treatment	Grade ≥ 3 Neutropenia	Overall RR	LRC	Metastatic Rate	OS
TAX 323 ¹⁵ (n=177)	TPF Arm	Radiation	77%	68%	52%	13%	37% (3 yr)
TAX 324 ^{16,17} (n=255)	TPF Arm	CT/RT	83%	72%	70%	5%	52% (5 yr)
UK H&N 11 (n=39)	Cb, P LDFRT 80 cGy D1,2	Variable	51%	82%	79.5%	23%	62% (5 yr)
UK H&N 15 (n=24)	Cb, P, LDFRT 50 cGy D1,2,8,15	Variable	24%	92%	87.5%	17%	79% (5 yr)

CT/RT = Chemoradiation, Cb=Carboplatin, P=Paclitaxel

Supplemental Table 2. Comparison of Response to Induction Therapy with Carboplatin and Paclitaxel

Author	Stage %			Cycles	Drugs	Primary Site Response %					Nodal Response %				
	II	III	IV			CR	PR	SD	PD	RR	CR	PR	SD	PD	RR
Dunphy ²² n=62	4	19	76	3	Cb, P	34	32	18	16	66	33	21	NR	NR	53
Bouillet ²⁴ n=20	N R	N R	N R	2	Cb, P	0	55	40	5	55	NR	NR	NR	NR	NR
Machtay ²³ n=53	0	35	65	2	Cb, P	13	76	NR	NR	89	NR	NR	NR	NR	NR
Vokes ¹⁵ N=69	0	4	96	2	Cb, P	30 [#] 35 [^]	45 [#] 57 [^]	3 [#] 3 [^]	3 [#] 3 [^]	75 [#] 87 [^]	NR	NR	NR	NR	NR
Arnold³⁴ n=39	0	23	77	2	Cb, P	28	62	10	0	90	31	38	28	3	69

Cb=Carboplatin, P=Paclitaxel, CR=Complete Response, PR=Partial Response, SD=Stable Disease, PD=Progressive Disease, RR=Response Rate, NR=Not Reported

* weekly doses, total for three weeks is in parenthesis

all patients from Vokes, et al (15)

^ evaluable patients only from Vokes, et al (15)